Patents Assigned to Roche Palo Alto LLC
  • Antibodies against CCR5 and uses thereof
    Patent number: 7615216
    Abstract: Antibodies that specifically bind to CCR5 are useful for treating immunosuppressive disease.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: November 10, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Michael Brandt, Surya Sankuratri, Ralf Schumacher, Stefan Seeber
  • Substituted pyrazolo[3,4-D]pyrimidines as p38 MAP kinase inhibitors
    Patent number: 7608603
    Abstract: Compounds of formula Ia, Ib, Ic, Id, Ie, If, Ig or Ih: wherein X and Y are nitrogen or one of X and Y is nitrogen and the other is CRg, and W, D, E, R4, R5, R6 and Rg are as defined herein. Also disclosed are methods of making the subject compounds and methods of using the compounds in the treatment of p38 MAP kinase-mediated diseases.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: October 27, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Nolan James Dewdney, Tobias Gabriel, Kristen Lynn McCaleb
  • Antiviral phosphoramidates
    Patent number: 7608599
    Abstract: The invention provides novel nucleoside compounds of formula I wherein R1, R2a, R2b, R3, R4, R5 R6, R8a, R9 and R10 are as defined herein which are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: October 27, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Klaus Klumpp, Joseph Armstrong Martin, Christopher McGuigan, David Bernard Smith
  • Phenylacetic acid compounds
    Patent number: 7608731
    Abstract: The present invention provides a process for the preparation 6-[3-(hetero)aryloxy-2-fluoro-benzyl]-2H-pyridazin-3-one compounds 1 where R2 is an optionally substituted aryl or an optionally substituted heteroaryl, R6 is NO2, NH2, alkyl, halogen, or a function group readily derived therefrom and R4c is hydrogen or alkyl. There also is provided a process for the preparation of phenylacetic acid compounds 2, wherein R2 and R6 are as defined previously and R5a is hydrogen or alkyl, which are useful for the preparation of pyridazinone compounds.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: October 27, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Denis John Kertesz, Michael Martin, Wylie Solang Palmer
  • 4?-Substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 7608601
    Abstract: The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: October 27, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
  • Substituted pyrazolo[3,4-d]pyrimidines as p38 MAP kinase inhibitors
    Patent number: 7601726
    Abstract: Compounds of formula Ia or Ib: wherein A, W, X, Y, R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and methods of using the compounds for treatment of p38 MAP kinase-mediated diseases.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: October 13, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Nidhi Arora, Nolan James Dewdney, Tobias Gabriel, Kristen Lynn McCaleb, Michael Soth
  • Methods for synthesis of 3-amino-1-arylpropyl indoles
    Patent number: 7598399
    Abstract: A method comprising: hydrogenating an indole propionamide compound of formula h with vitride, to form an aminopropyl indole compound of formula i wherein m, Ar, R1 and R2 are as defined herein. The compounds prepared by the method of the invention are useful as monoamine reuptake inhibitors useful for treatment of CNS indications.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: October 6, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Terrence Joseph Connolly, Robert P. Farrell, Eric Roy Humphreys, Stephen M. Lynch, Keshab Sarma
  • Tetrazole-substituted arylamides as P2Xand P2Xantagonists
    Patent number: 7595405
    Abstract: Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5 and R6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.
    Type: Grant
    Filed: June 28, 2007
    Date of Patent: September 29, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Michael Patrick Dillon, Ronald Charles Hawley, Li Chen, Lichun Feng, Minmin Yang
  • Diaminopyrimidines as P2Xand P2Xmodulators
    Patent number: 7589090
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the compounds being of formula (I): wherein R1, R2, R3 and R4 are as defined herein.
    Type: Grant
    Filed: February 27, 2008
    Date of Patent: September 15, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Michael Patrick Dillon, Alam Jahangir
  • Benzimidazolone and dihydroindolone derivatives and uses thereof
    Patent number: 7582760
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof wherein m, n, X, Ar, R1, R2, R3, R4 and R5 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: September 1, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Timothy Owens, Steven Sethofer, Keith Adrian Walker, Shu Hai Zhao
  • Tetralin and indane derivatives and uses thereof
    Patent number: 7576103
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1 and R2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: August 18, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Ralph New Harris, III, Nancy Elisabeth Krauss, James M. Kress, David Bruce Repke, Russell Stephen Stabler
  • Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors
    Patent number: 7566708
    Abstract: Compounds effective as p38 MAP kinase inhibitors, methods of making the compounds, and methods of using the compounds for treatment of p38 MAP kinase-mediated diseases.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: July 28, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Nidhi Arora, Roland Joseph Billedeau, Nolan James Dewdney, Tobias Gabriel, David Michael Goldstein, Counde O'Yang, Michael Soth, Teresa Alejandra Trejo-Martin
  • Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors
    Patent number: 7563799
    Abstract: Compounds of the formula Ia or Ib: wherein X and Y are N or one of X and Y is N and the other is CRg, and A, D, E, G, W, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the subject compounds and methods of using the compounds for treatment of p38 MAP kinase-mediated diseases.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: July 21, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Roland Joseph Billedeau, Nolan James Dewdney, Tobias Gabriel
  • Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors
    Patent number: 7563800
    Abstract: Compounds of formula Ia or Ib: wherein R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and methods of using the compounds for treatment of p38 MAP kinase-mediated diseases.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: July 21, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Tobias Gabriel, Yan Lou
  • Interferon-alpha polypeptides and conjugates
    Patent number: 7541163
    Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: June 2, 2009
    Assignees: Maxygen, Inc., Roche Palo Alto LLC
    Inventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse
  • Interferon-alpha polypeptides and conjugates
    Patent number: 7541436
    Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
    Type: Grant
    Filed: May 4, 2007
    Date of Patent: June 2, 2009
    Assignees: Maxygen, Inc., Roche Palo Alto LLC
    Inventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Andreas Schaubmar, Hans Koll
  • Interferon-alpha polypeptides and conjugates
    Patent number: 7537755
    Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
    Type: Grant
    Filed: August 15, 2007
    Date of Patent: May 26, 2009
    Assignees: Maxygen, Inc., Roche Palo Alto LLC
    Inventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Andreas Schaubmar, Hans Koll
  • Heterocyclic antiviral compounds
    Patent number: 7538122
    Abstract: This invention relates to piperidine derivatives of formulae Ia and Ib with substituents as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. More particularly, the present invention relates to 1-oxa-3,8-diaza-spiro[4.5]decan-2-one and 1-oxa-3,9-diaza-spiro[5.5]undecan-2-one compounds and related derivatives, to compositions containing and to uses of such derivatives. Disorders that may be treated or prevented by the present derivatives include HIV and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS), diseases of the immune system and inflammatory diseases.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: May 26, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Stephen Deems Gabriel, David Mark Rotstein
  • Imidazole derivatives
    Patent number: 7531529
    Abstract: The present invention relates to imidazole derivatives of formula I wherein R1, R2, R3 and R4 are described hereinabove. These compounds can be used in the treatment or prevention of mGluR5 receptor mediated disorders. These compounds are useful, inter alia, in the treatment of genitourinary diseases.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: May 12, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Bernd Buettelmann, Simona Maria Ceccarelli, Georg Jaeschke, Sabine Kolczewski, Richard Hugh Philip Porter, Eric Vieira, Anthony P. D. W. Ford, Yu Zhong
  • Diaminopyrimidines as P2Xand P2Xmodulators
    Patent number: 7531547
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): wherein D, X, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: May 12, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Michael Patrick Dillon, Alam Jahangir, Amy Geraldine Moore, Paul J. Wagner